Grace Therapeutics, Inc. Derivative Liability
Grace Therapeutics, Inc. (GRCE) had Derivative Liability of $3.33 million as of 2023-12-31, per its 10-Q filed 2024-02-12.
Discontinued › Balance Sheet › Liabilities
us-gaap:DerivativeLiabilities · last filed 2024-02-12
- 2023-12-31: Derivative Liability $3.33M.
- 2023-09-30: Derivative Liability $3.46M.
| Period end | Derivative Liability |
|---|---|
| 2023-12-31 | $3.33M 10-Q · filed 2024-02-12 |
| 2023-09-30 | $3.46M 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |